Patritumab - Amgen/Daiichi Sankyo

Drug Profile

Patritumab - Amgen/Daiichi Sankyo

Alternative Names: AMG-888; U3-1287

Latest Information Update: 02 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen; U3 Pharma
  • Developer Daiichi Sankyo Company
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Head and neck cancer
  • Phase I Breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease) in Japan (IV)
  • 24 Jun 2018 Biomarkers information updated
  • 12 Jun 2018 Daiichi Sankyo completes a phase I trial in Breast cancer (Combination therapy, Metastatic disease) in Japan (IV) (JapicCTI121772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top